Eric Lefkofsky
Founder and CEO @ Tempus
Chicago, United States
Eric Lefkofsky is a seed investor at Tempus in Chicago focused on E-Commerce and Mobile. Eric Lefkofsky is the Founder and CEO of Tempus. He previously worked at Echo Global Logistics as a Founder. Eric Lefkofsky attended the University of Michigan Law School.
- Total investments:
- 84
- Last investment:
- Lead investor:
- 30%
Last updated:
For AI agents: llms.txt
Industries Eric Lefkofsky invests in
Stages Eric Lefkofsky invests in
Countries Eric Lefkofsky invests in
Investment Focus
Industry
- E-Commerce 19 (23%)
- Mobile 15 (18%)
- Software 12 (14%)
- Internet 9 (11%)
- Advertising 7 (8%)
Stage
- Seed 31 (37%)
- Series A 17 (20%)
- Funding Round 16 (19%)
- Series B 6 (7%)
- Series C 5 (6%)
Country
- United States 62 (74%)
- United Kingdom 3 (4%)
- Canada 2 (2%)
- France 1 (1%)
- Israel 1 (1%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Inflow
|
Inflow delivers payment solutions that integrate affordability, efficiency, innovation, and tailored service. | $1.1M / Pre-Seed / Apr 21, 2025 | |
Ohana
|
Ohana is a company that allows users to find short-term housing and roommates. | $3M / Seed / Jun 17, 2024 | |
Basket
|
Basket is an AI-powered shopping companion transforming online retail into an agentic, ambient experience. By capturing SKU-level purchase intent across 300k+ users, Basket delivers personalised discovery, instant cashback, and automated savings through its universal shopping assistant. Acting as the consumer’s shopping OS, Basket unifieswishlisting, price comparison, gifting, and checkout into one seamless journey, redefining how people shop and how retailers connect with intent-driven audiences. | $2.8M / Seed / Oct 26, 2021 | |
Leap
|
Leap enables brands to deploy modern, immersive retail stores that drive growth and acquire customers. By leveraging millions of data points and a platform strategy, Leap makes physical retail more productive and less risky for brands. Its platform also follows a technology-enabled approach and includes all aspects of store development andoperations, including physical space, staffing, and managing all technology infrastructure that helps consumer brands to grow and deepen their customer brand experience.The company was founded in 2018 and is headquartered in New York City. | $11M / Series A / Aug 26, 2021 | |
Tempus
|
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of clinical and molecular data, and an operating system to make that data accessible and useful, Tempus enables physicians to make real-time, data-driven decisions todeliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. | $200M / Series G / Dec 10, 2020 | |
Blueprint
|
Blueprint helps mental health providers deliver effective treatment and make more money through digital measurement-based care.The company's mobile platform administers standardized and proprietary clinical assessments between appointments to help providers make more informed treatment decisions. Its assessments are reimbursable andautomated, so providers can use the Blueprint platform to generate additional revenue without extra work.Danny Freed headquartered the company in Chicago, Illinois in . | $3.4M / Seed / Dec 09, 2020 | |
Nubundle
|
Nubundle provides access to a concierge network of experienced family planning and fertility experts, preferred pricing at clinics and pharmacies, and just in time financing - all as a pass through employee benefit. | $1.5M / Seed / Nov 26, 2018 | |
SpotHero
|
SpotHero is the leading & only independent consumer marketplace for parking in North America. | $10.1M / Series C / Sep 06, 2018 | |
Exicure
|
Exicure is Formerly Known as AuraSense Therapeuticsis. Exicure is developing a new class of immunomodulatory and gene silencing drugs against validated targets. Our 3-dimensional, spherical nucleic acid (SNA™) architecture unlocks the potential of nucleic acid therapeutics in multiple organs. Our lead programs address diseases from inflammatorydisorders to oncology.SNA constructs overcome one of the most difficult obstacles to nucleic acid therapeutics: safe and effective delivery into cells and tissues. SNA constructs exhibit unparalleled transfection efficiency into numerous cell and tissue types including the skin without carriers or transfection agents. Moreover, SNAs can be used as potent immunotherapeutic agents for the treatment of cancer or infectious disease. | $20M / Sep 27, 2017 | |
|
Exicure
|
Exicure is Formerly Known as AuraSense Therapeuticsis. Exicure is developing a new class of immunomodulatory and gene silencing drugs against validated targets. Our 3-dimensional, spherical nucleic acid (SNA™) architecture unlocks the potential of nucleic acid therapeutics in multiple organs. Our lead programs address diseases from inflammatorydisorders to oncology.SNA constructs overcome one of the most difficult obstacles to nucleic acid therapeutics: safe and effective delivery into cells and tissues. SNA constructs exhibit unparalleled transfection efficiency into numerous cell and tissue types including the skin without carriers or transfection agents. Moreover, SNAs can be used as potent immunotherapeutic agents for the treatment of cancer or infectious disease. | $20M / Sep 27, 2017 | |
| See all 84 investments → | |||
Co-Investors
About Tempus
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of clinical and molecular data, and an operating system to make that data accessible and useful, Tempus enables physicians to make real-time, data-driven decisions todeliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data.
Tempus Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Eric Lefkofsky
Founder and CEO
|
|||
Jonathan Ozeran
Director of Product
|
|||
Andrew Polovin
General Counsel
|
|||
Kimberly Yeatts
Vice President of Clinical Lab Operations
|
|||
Martin Stumpe
Chief of AI
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Eric Lefkofsky invest in?
Eric Lefkofsky invests primarily in E-Commerce, Mobile and Software startups, most often at Seed and Series A stage. Most of the 84 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Eric Lefkofsky last invest?
The most recent investment recorded for Eric Lefkofsky closed in Apr 2025. Shizune tracks 84 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
